| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 44.63▲ | 44.54▲ | 44.56▲ | 43.27▲ | 41.36▲ |
| MA10 | 44.53▲ | 44.47▲ | 44.56▲ | 41.93▲ | 40.64▲ |
| MA20 | 44.53▲ | 44.52▲ | 43.92▲ | 40.73▲ | 38.02▲ |
| MA50 | 44.50▲ | 43.21▲ | 42.21▲ | 40.39▲ | 36.43▲ |
| MA100 | 44.54▲ | 42.06▲ | 40.95▲ | 37.77▲ | 39.24▲ |
| MA200 | 43.99▲ | 40.71▲ | 41.15▲ | 35.81▲ | 37.38▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.020▲ | -0.081▼ | -0.042▼ | 0.502▲ | 0.559▲ |
| RSI | 58.079▲ | 63.554▲ | 70.850▲ | 71.271▲ | 64.980▲ |
| STOCH | 77.885 | 71.221 | 63.105 | 83.988▲ | 63.771 |
| WILL %R | -10.526▲ | -13.953▲ | -18.605▲ | -3.978▲ | -3.082▲ |
| CCI | 122.876▲ | 69.386 | 54.638 | 163.697▲ | 156.633▲ |
|
Tuesday, November 25, 2025 05:36 AM
Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with ...
|
|
Monday, November 17, 2025 09:40 AM
Xenon Pharmaceuticals Inc (XENE) exceeds patient enrollment goals in its Phase 3 XTOL2 study and maintains a robust cash runway into 2027, despite facing market competition and upcoming expenses.
|
|
Thursday, November 06, 2025 12:30 AM
VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 28/11/25 | 44.68 | 44.81 | 43.90 | 44.72 | 234,635 |
| 26/11/25 | 43.94 | 45.01 | 43.82 | 44.49 | 1,070,900 |
| 25/11/25 | 42.50 | 44.21 | 42.405 | 43.94 | 1,089,800 |
| 24/11/25 | 41.09 | 42.15 | 40.64 | 42.05 | 969,100 |
| 21/11/25 | 40.12 | 41.50 | 39.09 | 41.16 | 626,000 |
| 20/11/25 | 41.36 | 42.305 | 40.22 | 40.27 | 779,700 |
| 19/11/25 | 40.62 | 41.06 | 40.28 | 40.65 | 559,200 |
| 18/11/25 | 40.46 | 41.31 | 40.27 | 40.61 | 749,763 |
| 17/11/25 | 40.76 | 41.58 | 40.305 | 40.61 | 951,900 |
| 14/11/25 | 39.86 | 41.18 | 39.86 | 40.76 | 1,041,379 |
|
|
||||
|
|
||||
|
|